Drug Trial Radar · NCT07148960
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
300
Planned (sponsor's estimate)
Start
Sep 15, 2025
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- West Virginia UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will decrease duration of bacteremia (\< 6 days) and improve outcomes compared to single IV antibiotic therapy. The main questions this study aims to answer are: * To decrease SAB duration and improve outcomes by using early dual vs. single agent IV antibiotic therapy * To accelerate practice transformation of earlier IV to oral (PO) antibiotic transition by switching to PO antibiotic therapy once blood cultures are negative at 72 hours Participants will be asked to agree to be randomized (like flipping a coin) to receive two or one IV antibiotic(s). Once the infection has cleared, the treatment will be changed to PO antibiotics. As part of usual care, participants will have weekly lab tests for monitoring while on antibiotics, receive a telephone call to see how the participants are doing, and follow up in person or by telephone or video in Infectious Diseases (ID) Clinic. Participant participation will last 12 weeks after the participant is discharged from the hospital.
Conditions
- Staphylococcus Aureus Bacteremia
Interventions
Early Dual IV Antibiotic Therapy - MRSADrug
Participant given IV daptomycin plus ceftaroline dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
Early Dual IV Antibiotic Therapy - MSSADrug
Participant given IV cefazolin plus ertapenem dosing per standard of care. Oral rifampin may be added for participants with prosthetic material.
Single Agent IV Antibiotic Therapy - MRSADrug
Participant given one of the following IV therapies: daptomycin, vancomycin, or ceftaroline. Oral rifampin may be added for participants with prosthetic material.
Single Agent IV Antibiotic Therapy - MSSADrug
Participant given one of the following IV therapies: cefazolin, oxacillin, or nafcillin. Oral rifampin may be added for participants with prosthetic material.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with prolonged bacteremia (≥ 6 days)Time frame: Up to 12 weeks post hospital discharge
- Seeding of a New Site - IncidenceTime frame: Up to 12 weeks post hospital discharge
- All-Cause MortalityTime frame: Up to 12 weeks post hospital discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West Virginia University
Morgantown, West Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.